Thursday’s weakness in Cytokinetics’ (CYTK) shares is likely due to commentary from Bristol Myers’ (BMY) earnings call, where the company highlighted an April PDUFA date where the Food and Drug Administration will review and possibly relax the REMS/ Echo monitoring requirement for Camzyos that competes with Cytokinetcs’ aficamten, Truist tells investors. The firm thinks the pressure on Cytokinetics’ shares may be overdone given what the firm sees as a competitive profile for aficamten. Truist has a Buy rating and $70 price target on Cytokinetics shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Netflix upgraded, Reddit downgraded: Wall Street’s top analyst calls
- Cytokinetics initiated with a Buy at Stifel
- Cytokinetics announces start of AMBER-HFpEF, Phase 2 trial of CK-586
- Cytokinetics CEO not looking to be bought, but would listen, STAT says
- Cytokinetics provided milestones expected in 2025